

1FW



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on June 27, 2006

INFORMATION DISCLOSURE  
STATEMENT  
Examining Group 1614  
Patent Application  
Docket No. INN-123  
Serial No. 10/537,394

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Applicants : Francois Romagne, H  len   Sicard, J  r  me Tiollier  
Serial No. : 10/537,394  
Filed : June 2, 2005  
Conf. No. : 8478  
For : Compositions and Methods for Regulating an Immune Response in a Subject

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR   1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC   371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PTO/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, Applicants have not submitted a copy of the U.S. patent or the published U.S. Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii). In accordance with 37 CFR   1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.


Published International No. WO 00/59916, cited as F1 on the attached form PTO/SB/08, and published International No. WO 03/009855, cited as F3 on the attached form PTO/SB/08, are written in a foreign language. In accordance with MPEP §609A(3), Applicants are submitting herewith a copy of the International Search Report from corresponding International Application No. PCT/IB03/06375 which was filed on December 2, 2003. Applicants have also included U.S. Patent No. 6,624,151 and CA 2,453,817, cited as U2 and F4, respectively, on the attached form PTO/SB/08.

The U.S. patent and Canadian patent application are cited on the International Search Report as a patent family member of WO 00/59916 and WO 03/009855, respectively, and are believed to be an English language equivalents. Applicants note that although the specifications of the WO 00/59916 and WO 03/009855 applications are written in a foreign language, an English language Abstract is provided therewith. Applicants respectfully request that these references be made of record and considered in the examination of the subject application.

Applicants note that published International Application No. WO 00/12519, cited as F2 on the attached form PTO/SB/08, was written in a foreign language. However, an English language abstract is provided in the reference. Applicants respectfully request that the reference be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references; copy of International Search Report



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/537,394
				Filing Date	June 2, 2005
				First Named Inventor	Francois Romagne
				Art Unit	1614
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	INN-123

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2002/142996 A1	10-03-2002	Green <i>et al.</i>	All
	U2	US-6,624,151 B1	09-23-2003	Belmant <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 00/59916	10-12-2000	Institut National de la Sante et de la Recherche Medicale	All	X
	F2	WO 00/12519	03-09-2000	Institut National de la Sante et de la Recherche Medicale	All	
	F3	WO 03/009855	02-06-2003	Jomaa Pharmaka GMBH	All	X
	F4	CA 2,453,817	06-02-2003	Bioagency AG	All	
	F5					

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/537,394		
		Filing Date	June 2, 2005		
		First Named Inventor	Francois Romagne		
		Group Art Unit	1614		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	INN-123

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	KUNZMAN, V. <i>et al.</i> "Stimulation of $\gamma\delta$ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma" <i>Blood</i> , 2000, pp. 384-392, Vol. 96, No. 2.	
	R2	WILHELM, M. <i>et al.</i> " $\gamma\delta$ T cells for immune therapy of patients with lymphoid malignancies" <i>Blood</i> , 2003, pp. 200-206, Vol. 102, No. 1.	
	R3	DATABASE PROMT, December 15, 2003, XP002276950, retrieved from STN, Database accession no. 2003:627750, abstract only, "Phosphostim Innate Pharma partnering opportunity, Worldwide (solid tumor) Innate Pharma phase change I, France (solid tumor)" <i>RD Focus Drug News</i> .	
	R4	DATABASE PHIN, March 8, 2002, XP002276951, retrieved from STN, Database accession no. 2002:6085, abstract only, "Innate gets Euros 2 million loan from French agency" <i>SCRIP</i> , no. 2727, page 7.	
	R5	DATABASE CBNB, November-December 2002, XP002276952, retrieved from STN Database accession no. 19(9):12851, abstract only, "Innate Pharma exceeds objectives in obtaining funding for first clinical trials", <i>PhamaChem</i> , Vol. 1, Nos. 11-12.	
	R6	MONTALVETTI, A. <i>et al.</i> "Farnesyl Pyrophosphate Synthase is an Essential Enzyme in <i>Trypanosoma brucei</i> . <i>In vitro</i> RNA Interference and <i>in vivo</i> Inhibition Studies" <i>J. Biol. Chem.</i> , May 9, 2003, pp. 17075-17083, Vol. 8, No. 19.	
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.